To determine the cost-effectiveness of interventions for major depression in Thailand. METHODS: A microsimulation model was developed to describe the course of disease in individuals. Model inputs included Thai data on disease parameters and costs while impact measures are derived from a systematic review and meta-analysis of the international literature. Results are presented as cost (Thai Baht) per disability adjusted life-year (DALY) averted, compared to the null scenario (do nothing). Fluoxetine as the cheapest antidepressant drug in Thailand was analyzed for treatment of episodes plus a 6 month continuation phase and for maintenance treatment over 5 years of follow-up. Cognitive behavioral therapy (CBT) was analyzed for episodic treatment and for 5-year maintenance treatment. RESULTS: The incremental cost-effectiveness ratios (ICER) of fl uoxetine for episodic treatment with or without a continuation or maintenance phase are just below one times GDP per capita in Thailand of 110,000 Baht. CBT during an episode of depression (ICER = 39,000) is more costeffective than medications (ICER = 88,000); a maintenance version of CBT is the most cost-effective option with an ICER of 27,000. Episodic drug treatment has the lowest cost (250 Million Baht) and averts 3000 DALYs. Episodic treatment with CBT, which has an ongoing effect for 1.5 years, costs 100 Million Baht more than drug treatment but it averts more than 6000 DALYs compared to drugs. CONCLUSIONS: CBT is the most cost-effective treatment option for both episodic and maintenance treatment. Maintenance treatment is the more cost-effective of the two. However, there is currently a lack of mental health personal, especially psychiatrists and psychologists, who would be expected to deliver CBT in Thailand. Antidepressant drugs are quite a bit less effective but also less costly than CBT.
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COST-EFFECTIVENESS OF TYPICALS, ATYPICALS AND PSYCHOSOCIAL INTERVENTIONS FOR SCHIZOPHRENIA IN THAILAND
Phanthunane P 1 , Vos T 2 , Whiteford H 1 , Bertram M 2 1 University of Queensland, Brisbane, QLD, Australia; 2 The University of Queensland, Brisbane, Queensland, Australia OBJECTIVES: To determine the optimal treatment package, including drug and non drug interventions, for schizophrenia in Thailand. METHODS: A Markov model was used to evaluate the cost-effectiveness of typical antipsychotics, generic risperidone, olanzapine, clozapine and family interventions. Health outcomes were measured in disability adjusted life-years. We considered health outcomes from a change in disease severity; extrapyradimal symptoms and weight gain as side effects; and a reduction in suicide (for clozapine only). Intervention costs included treatment cost, hospitalization cost as well as time and travel cost of patients and families. Uncertainty was evaluated using multivariate Monte Carlo simulation. As a generic version of risperidone is expected on the market soon, a sensitivity analysis of varying costs of risperidone was undertaken. RESULTS: The cost-effectiveness results indicate generic risperidone, assuming a cost of 4 baht per 2-mg tablet will improve health outcomes and save costs if replacing the currently predominant treatment of typical drugs. The ideal combination of treatments is risperidone as fi rst line treatment (dominant intervention), adding family interventions for all patients (Incremental cost-effectiveness ratio of 2000 baht/ DALY) and adding clozapine to severe patients (an estimated 33% of patients). This addition has an incremental cost-effectiveness ratio of 290,000 baht/DALY, which is still less than three times GDP per capita. CONCLUSIONS: The introduction of generic risperidone will lead to more effi cient outcomes and lower costs if it can be produced for less than 10 baht per 2-mg tablet. Providing family interventions for all patients and treating more severe patients with clozapine can further improve outcomes of Thai patients with schizophrenia in a cost-effective manner.
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PMH13 ASSOCIATION OF MEDICATION PERSISTENCE AND HEALTH-CARE UTILIZATION IN HIGH-COST PATIENTS WITH MAJOR DEPRESSIVE DISORDER TREATED WITH DULOXETINE OR VENLAFAXINE XR
Liu X 1 , Tepper P 2 , Mullins CD 3 , Faries D 1 , Johnstone B 1 1 Eli Lilly and Company, Indianapolis, IN, USA; 2 University of Pittsburgh, Pittsburgh, PA, USA; 3 University of Maryland School of Pharmacy, Baltimore, MD, USA OBJECTIVES: Adequate duration of antidepressant therapy is essential for the treatment of major depressive disorder (MDD). This study examined the association between medication persistence and hospitalization and emergency room (ER) visit for high-cost patients with MDD in the usual clinical setting. METHODS: In a large US commercial managed-care claims database, 8177 MDD patients (18 to 64 years old) were initiated on duloxetine or venlafaxine XR during the calendar year 2006. All of the patients had no active prescription of study medications for 6 months prior to initiation and had continuous enrollment for 12 months prior to and postmedication initiation. High-cost patients were defi ned as patients whose total treatment costs in the prior 1 year were above the median of total costs for all MDD patients in 2005 (n = 5093). After propensity-score matching on observed variables known to affect medication choices, 1714 duloxetine patients and an equal number of venlafaxine XR patients were included for this analysis. Medication persistence was defi ned as the length of therapy without exceeding a 15-day gap. Logistic regression analyses were used to examine the associations between medication persistence and health-care utilization in the year following treatment initiation. RESULTS: In the post 1 year, duloxetine patients stayed on the medication signifi cantly longer (119.5 vs. 110.4 days, P = 0.047) than venlafaxine XR patients. Treatment persistence >3 months was signifi cantly associated with reduced odds of psychiatric hospitalization (OR = 0.46, 95% CI = 0.37-0.58), nonpsychiatric hospitalization (OR = 0.77, 95% CI = 0.64-0.92), and ER visit (OR = 0.69, 95% CI = 0.60-0.79). Treatment differences in health-care utilization were not statistically signifi cant. These fi ndings had no essential changes with adjustment for demographics, comorbid conditions, and prior health-care utilization and separate analyses for duloxetine and venlafaxine XR patients. CONCLUSIONS: Duloxetine therapy appears to have longer persistence than venlafaxine XR for high-cost patients with MDD. Medication persistence >3 months is associated with reduced hospitalization and ER visit.
PMH14 ADHERENCE AND PERSISTENCE WITH DULOXETINE VERSUS ESCITALOPRAM AMONG HIGH HEALTH-CARE RESOURCES UTILIZERS WITH MAJOR DEPRESSIVE DISORDER
Tepper P 1 , Liu X 2 , Able SL 2 , Johnstone B 2 1 University of Pittsburgh, Pittsburgh, PA, USA; 2 Eli Lilly and Company, Indianapolis, IN, USA OBJECTIVES: Adherence and persistence to prescribed medication is important in the management of major depressive disorder (MDD). This study compared adherence and persistence between duloxetine and escitalopram among high health-care utilizers with MDD. METHODS: In a large US commercial managed-care claims database, 10,803 MDD patients (18 to 64 years) who initiated on duloxetine (n = 4542) or escitalopram (n = 6261) during the calendar year 2006 were identifi ed. All of the patients had no recorded prescription of study medications for 6 months prior to initiation and had continuous enrollment for 12 months prior to and post-medication initiation. High health-care utilizers (duloxetine, n = 3113; escitalopram, n = 3157) were defi ned as patients whose total treatment costs in the prior 1 year were above the median of total costs for all MDD patients in 2005. Adherence was defi ned as Medication Possession Ratio (MPR) ≥0.8, and persistence was defi ned as the length of therapy without exceeding a 30-day gap. Statistical analyses included chi-square test, Wilcoxon rank sum test, multivariate logistic and Cox regression. RESULTS: In the post 6 months (6M) and 12 months (12M), adherence rates were signifi cantly higher for duloxetine-treated patients (6M 54.6% and 12M 40.9%) than escitalopram-treated patients (6M 47.4% and 12M 31.7%) (P-values < 0.001). Duloxetinetreated patients also stayed on the medication signifi cantly longer (6M 115.9 days and 12M 171.1 days) than escitalopram-treated patients (6M 108.4 days and 12M 154.6 days) (P-values < 0.001). Results were essentially unchanged with adjustment for demographics, comorbid conditions, prior medications use, and health-care utilization, resulting in duloxetine therapy maintaining its better adherence and longer persistence versus escitalopram. CONCLUSIONS: Duloxetine-treated patients appear to be more adherent and have a longer stay on the medication than escitalopramtreated patients for high resources utilizers. Further research is needed to examine clinical and economic benefi ts of better adherence and persistence with duloxetine therapy.
PMH15 THE VALIDATION OF TWO MEASURES ASSESSING REASONS FOR ANTIPSYCHOTIC DISCONTINUATION AND CONTINUATION FROM PATIENTS' AND CLINICIANS' PERSPECTIVES
Faries D, Ascher-Svanum H, Nyhuis A, Anderson J, Phillips G Eli Lilly and Company, Indianapolis, IN, USA OBJECTIVES: Treatment discontinuation is an important effectiveness measure for evaluating antipsychotic treatment, yet is typically assessed only on a high level (e.g., "lack of effi cacy," "adverse event," or "patient decision"). The RAD-I was developed as a structured interview assessing patient's perspective regarding specifi c reasons for antipsychotic discontinuation and continuation and the RAD-Q as a questionnaire assessing clinician's perspective. This study assessed the validity of the RAD measures in a randomized clinical trial. METHODS: The RAD was assessed at baseline (referring to medications prior to the trial) and endpoint (referring to discontinuation/ continuation of study drug) in a 12-week schizophrenia clinical trial. To assess its psychometric properties, we examined content validity, discriminate validity, and agreement between RAD scales using endpoint data (N = 158). RESULTS: Of 29 potential primary reasons for medication discontinuation, the most common was insuffi cient improvement/worsening of positive symptoms (24%) followed by adverse events (22%). A high level of concurrent validity was observed, as 89% of patients discontinuing medication due to "lack of effi cacy" (87%, "adverse events") per the standard trial form had lack of effi cacy ("adverse events") as a primary or very important reason on the RAD. Patients indicating lack of improvement/worsening of positive symptoms as a primary reason for medication discontinuation on the RAD had signifi cantly less improvement in PANSS positive score than patients not reporting this as a reason. Similar results were observed for the RAD mood items (per MADRS) and functional status (per QLS) as well as for corresponding analyses assessing reasons for continuation. Agreement between the clinician and patient scores was high (range 73% to 100%). CONCLUSIONS: This initial psychometric assessment suggests the RAD is a valid tool for gathering detailed information regarding reasons for antipsy-
